en · de · es · fr · pt
tb-500-notes.peptides9002.com › Topic › Thymosin Beta-4 Fragment Identity — Background and Details

Thymosin Beta-4 Fragment Identity — Background and Details

By Editorial Desk · published 2026-02-17 · last reviewed 2026-03-12 · Topic

actin binding raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-03-12 and is reviewed periodically as new material appears.

Thymosin Beta-4 Fragment Identity

No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.

TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.

Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.

Identification and Molecular Background

Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.

Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.

Tb-500 at a glance

PropertyValueNotes
Molecular massApproximately 4963 Da for full-length thymosin beta-4Value applies to the parent protein; fragment products may differ
AppearanceWhite to off-white lyophilized powderTypical form of supplied synthetic peptide
SolubilityFreely soluble in waterPolar peptide; dissolves readily in aqueous buffer
Storage of dry powder−20 °C, desiccated, protected from lightStandard laboratory practice for peptides
Typical detection methodLiquid chromatography–tandem mass spectrometryUsed in purity testing and anti-doping analysis

Research Framing and Evidence Base

Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.

Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.

Related pages on this site

Identity and Research Background

Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.

Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.

TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.

Background from the literature

Hydroxyl radicals are highly reactive and undergo chemical reactions that make them short-lived. When biological systems are exposed to hydroxyl radicals, they can cause damage to cells, including those in humans, where they can react with DNA, lipids, and proteins.

Cantrell refused to comment on the singer's appearance, and band manager Susan Silver said she had not seen him since "last year". Staley made his final public appearance on October 31, 1998, when he attended a Jerry Cantrell solo concert in Seattle. He declined Cantrell's request to sing with him on stage. A photo taken of Staley backstage at this show is the most recent photo of him that has been publicly released. Thereafter, Staley was thought to have left behind his "self-imposed rock & roll exile", when in November 1998 he laid down additional vocal tracks as part of a supergroup called Class of '99, featuring members of Rage Against the Machine, Jane’s Addiction, and Porno for Pyros. On July 19, 1999, the radio program Rockline was hosting Cantrell, Inez, and Kinney for a discussion on the release of Nothing Safe: Best of the Box, when, unexpectedly, Staley called in to participate. This was Staley's last interview. From 1999 to 2002, Staley became more reclusive and depressed, rarely leaving his Seattle condo; little is known about the details of his life during this period. Staley was rumored to spend most of his days creating art, playing video games, or nodding off on drugs. Staley's one-time roommate and friend Morgen Gallagher later said that around 2001 Staley said he was asked to audition for Audioslave; this claim was later debunked by Audioslave guitarist Tom Morello.

Fleming resumed his vacation and returned in September. According to his notes on 30 October, he collected the original mould and grew it in culture plates. After four days he found that the plates developed large colonies of the mould. He repeated the experiment with the same bacteria-killing results. He later recounted his experience:

=== Ketoacidosis === Ketoacidosis is a pathological state of uncontrolled production of ketones that results in a metabolic acidosis, with serum ketone levels typically in excess of 3 mM. Ketoacidosis is most commonly caused by a deficiency of insulin in type 1 diabetes or late stage type 2 diabetes but can also be the result of chronic heavy alcohol use, salicylate poisoning, or isopropyl alcohol ingestion. Ketoacidosis causes significant metabolic derangements and is a life-threatening medical emergency. Ketoacidosis is distinct from physiological ketosis as it requires failure of the normal regulation of ketone body production.

Sources: en.wikipedia.org

Further detail

=== Symbiosis === Once the fungal hyphae make contact with root cap cells, they must continue to grow inwards to the epidermal cells and multiply to form the layers that will eventually produce the mantle. Production of the fungal mantle involves the upregulation of genes responsible for translation and cell growth, as well as those responsible for membrane synthesis and function, such as hydrophobins. Some polypeptides are only found when the fungus and plant have achieved symbiosis; these symbiosis-related (SR) proteins are termed ectomycorrhizins. Major changes in polypeptide and mRNA synthesis happen rapidly after colonization by the fungus, including the production of ectomycorrhizins. Changes include the upregulation of genes that may help new membranes to form at the symbiotic interface. The effect of the mantle on root proliferation, root hair development and dichotomous branching can be partially mimicked by fungal exudates, providing a path to identifying the molecules responsible for communication. The Hartig net initially forms from the fully differentiated inner layer of the mantle, and penetration occurs in a broad front oriented at right angles to the root axis, digesting through the apoplastic space. Some plant cells respond by producing stress- and defense-related proteins including chitinases and peroxidases that could inhibit Hartig net formation.

== Plot == Nathan is currently in Switzerland, living as a nomad. He has been unsuccessfully searching for the Fairborn, a knife that can only be used by Nathan's bloodline. His friend, Gabriel, is missing. Nathan meets Nesbitt, who is half fain and half Black witch. When they are ambushed by Hunters, Nesbitt catches one, while the other, Kieran, Annalise's brother, turns invisible. It is then that Nathan feels the animal in him, and he kills Kieran. The next day, Nesbitt brings Nathan to Van, his employer. Van informs Nathan that Soul, Annalise's uncle, has taken charge of the Council of White Witches and is letting a witch named Wallend experiment on Black witches.

Biological differences in fractionation stem not only from biochemical differences between different molecules, but also from physiological differences between different organisms. For example, the δDs of multiple leaf wax molecules are enriched in shrubs (median ~ −90‰) relative to trees (median ~ −135‰), which themselves are enriched relative to both C3 (median ~ −160‰) and C4 grasses (median ~ −140‰). Between individual species, substantial variation in δD has been documented. Other physiological factors that contribute to variable leaf wax δD values include the seasonal timing of leaf development, response to external stress or environmental variability, and the presence or absence of stomata It can be difficult to distinguish between physiological factors and environmental factors, when many physiological adaptations are directly related to environment. Several environmental factors have been shown to contribute to leaf wax δD variability, in addition to environmental effects on the δD of source water. Humidity is known to impact lipid δD at moderate humidity levels, but not at particularly high (>80%) or low (<40%) humidity levels, and a broad trend of enriched δDs, meaning smaller εl/w, is seen in arid regions. Temperature and sunlight intensity, both correlated to latitude, have strong effects on the rates of metabolism and transpiration, and by extension on εl/w. Also, the average chain length of leaf wax molecules varies with geographic latitude, and εl/w has been shown to increase with increasing chain length.

Sources: en.wikipedia.org

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.

Has any regulator approved TB-500 for medical use?

No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.

Why does TB-500 appear in anti-doping literature?

It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.

What is TB-500 chemically?

It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.

Network